Actively Recruiting

Age: 40Years - 75Years
All Genders
ID03437486

Mechanisms of Familial Pulmonary Fibrosis

Led by Vanderbilt University Medical Center · Updated on 2025-12-31

750

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are conducting a long-term observational study focused on first-degree family members of patients diagnosed with familial interstitial pneumonia (FIP), a hereditary form of idiopathic pulmonary fibrosis (IPF). FIP is characterized by at least two blood relatives with idiopathic interstitial pneumonia. The study aims to better understand the natural history of FIP and identify risk factors for developing symptoms, as individuals have about a 50% chance of carrying a disease-related gene. The study expects to follow participants yearly through age 75 or until symptomatic FIP develops. Participants without prior lung disease and with mild or no shortness of breath will be invited to undergo evaluations including high-resolution CT scans, pulmonary function tests, and blood draws. Over the years 2024-2029, additional questionnaires, urine samples, and wearable device use will explore environmental influences. Every three years, participants may return for repeat testing to monitor changes that could predict pulmonary fibrosis development. Subjects with more severe symptoms or extensive disease findings will be advised to seek clinical evaluation outside the study. Throughout participation, researchers will collect demographic and medical history data, and annually check for new respiratory symptoms, diagnostic testing, or treatments related to lung disease. If symptoms develop, medical records and imaging will be reviewed by specialists to classify disease status. The main outcome measured is the clinical diagnosis of interstitial lung disease, with follow-up expected to last about 10 years and up to six total collections of blood, CT scans, and lung function tests per participant.

CONDITIONS

Brief Title

Mechanisms of Familial Pulmonary Fibrosis

Who Can Participate

Age: 40Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Bloodline members of a family with two or more relatives diagnosed with idiopathic interstitial pneumonia (IIP) who do not have a personal diagnosis of IIP or IPF
  • Sibling or adult child of an affected individual
  • Age between 40 and 75 years old, or between 18 and 40 if the affected relative was diagnosed before age 50
  • No prior history of lung disease and a dyspnea score of 2 or less
  • Willingness and ability to complete questionnaires and attend study visits
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide informed consent
  • Unable to travel for 1-2 outpatient visits or complete required questionnaires
  • Age under 40 or over 75 years old, unless qualifying by relative's diagnosis age
  • Presence of diseases with symptoms similar to IIP or IPF, such as rheumatoid arthritis, connective tissue diseases, or occupational lung disease
  • Considered unsuitable for participation by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Initial evaluation and repeated every 3 years for up to 10 years

Participants undergo research evaluation including HRCT scanning, pulmonary function testing, blood draw, and questionnaires to assess lung health and environmental factors.

Up to 6 visits approximately every 3 years

Long-term Monitoring

Duration - Up to 10 years after enrollment

Participants are contacted annually for follow-up to check for respiratory symptoms, additional diagnostic testing, or new treatments related to lung disease.

Annual contact (remote or in-person) for follow-up

Trial Site Locations

Total: 1 location

1

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

Loading map...

Research Team

T

Tisra H Fadely, BSN, RN

C

Cheryl Markin, BS

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase I, Single-center, Randomized, Double-blind, Single-d...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

An Open-label Extension Trial of the Long-term Safety and Ef...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

373 locations

A Randomized, Double-blind, Placebo-controlled, Single and M...

Idiopathic Pulmonary Fibrosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here